| Trial ID: | L3052 |
| Source ID: | NCT06553248
|
| Associated Drug: |
Gzr4
|
| Title: |
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: GZR4|DRUG: Insulin Degludec
|
| Outcome Measures: |
Primary: Incidence of TEAE, Baseline to Week 6 | Secondary: AUC0-inf, Week 6|AUC0-last, Week 6|AUC0-168h, Week 1, Week 6|Tmax,GZR4, Week 1, Week 6|ADA of GZR4, Baseline to Week 10
|
| Sponsor/Collaborators: |
Sponsor: Gan and Lee Pharmaceuticals, USA
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-03-22
|
| Completion Date: |
2023-11-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-14
|
| Locations: |
Gan & Lee Pharmaceuticals Co., Ltd, Beijing, Beijing, 100000, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06553248
|
